BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nirogi R, Shinde A, Mohammed AR, Badange RK, Reballi V, Bandyala TR, Saraf SK, Bojja K, Manchineella S, Achanta PK, Kandukuri KK, Subramanian R, Benade V, Palacharla RC, Jayarajan P, Pandey S, Jasti V. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity. J Med Chem 2019;62:1203-17. [PMID: 30629436 DOI: 10.1021/acs.jmedchem.8b01280] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Nirogi R, Ajjala DR, Prakash Padala NS, Kalaikadhiban I, Rayapati LP, Chunduru P, Shinde A. LC-MS/MS method for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist for narcolepsy treatment. Bioanalysis 2020;12:533-44. [PMID: 32351118 DOI: 10.4155/bio-2020-0020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Nirogi R, Grandhi VR, Medapati RB, Ganuga N, Benade V, Gandipudi S, Manoharan A, Abraham R, Jayarajan P, Bhyrapuneni G, Shinde A, Badange RK, Subramanian R, Petlu S, Jasti V. Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders. J Psychopharmacol 2021;35:713-29. [PMID: 33546570 DOI: 10.1177/0269881120986418] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Nirogi R, Bhyrapuneni G, Muddana NR, Manoharan A, Shinde AK, Mohammed AR, Padala NP, Ajjala DR, Subramanian R, Palacharla VRC. Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy. European Journal of Pharmaceutical Sciences 2020;152:105425. [DOI: 10.1016/j.ejps.2020.105425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Bolshakov AP, Stepanichev MY, Dobryakova YV, Spivak YS, Markevich VA. Saporin from Saponaria officinalis as a Tool for Experimental Research, Modeling, and Therapy in Neuroscience. Toxins (Basel) 2020;12:E546. [PMID: 32854372 DOI: 10.3390/toxins12090546] [Reference Citation Analysis]
6 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
7 Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology (Berl) 2021;238:1495-511. [PMID: 33550481 DOI: 10.1007/s00213-021-05779-x] [Reference Citation Analysis]
8 Nirogi R, Mudigonda K, Bhyrapuneni G, Muddana NR, Shinde A, Goyal VK, Pandey SK, Mohammed AR, Ravula J, Jetta S, Palacharla VRC. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. Clin Drug Investig 2020;40:603-15. [DOI: 10.1007/s40261-020-00920-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Iwamatsu C, Hayakawa D, Kono T, Honjo A, Ishizaki S, Hirayama S, Gouda H, Fujii H. Effects of N-Substituents on the Functional Activities of Naltrindole Derivatives for the δ Opioid Receptor: Synthesis and Evaluation of Sulfonamide Derivatives. Molecules 2020;25:E3792. [PMID: 32825410 DOI: 10.3390/molecules25173792] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ernouf G, Chirkin E, Rhyman L, Ramasami P, Cintrat J. Photochemical Strain‐Release‐Driven Cyclobutylation of C(sp 3 )‐Centered Radicals. Angew Chem Int Ed 2020;59:2618-22. [DOI: 10.1002/anie.201908951] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
11 Ancheta LR, Shramm PA, Bouajram R, Higgins D, Lappi DA. Saporin as a Commercial Reagent: Its Uses and Unexpected Impacts in the Biological Sciences—Tools from the Plant Kingdom. Toxins 2022;14:184. [DOI: 10.3390/toxins14030184] [Reference Citation Analysis]
12 Shinde AK, Badange RK, Reballi V, Achanta PK, Bojja K, Manchineella S, Rao Muddana N, Subramanian R, Choudary Palacharla R, Benade V, Jayarajan P, Thentu JB, Lingavarapu BB, Yarra S, Kagita N, Rao Doguparthi M, Mohammed AR, Nirogi R. 1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition. ChemMedChem 2021. [PMID: 34761873 DOI: 10.1002/cmdc.202100583] [Reference Citation Analysis]
13 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
14 Ernouf G, Chirkin E, Rhyman L, Ramasami P, Cintrat J. Photochemical Strain‐Release‐Driven Cyclobutylation of C(sp 3 )‐Centered Radicals. Angew Chem 2020;132:2640-4. [DOI: 10.1002/ange.201908951] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]